Halozyme Therapeutics annual net debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Halozyme Therapeutics Net Debt Growth & History (HALO)
Halozyme Therapeutics's net debt was $2.04B for fiscal 2025.
View full Halozyme Therapeutics company overviewHalozyme Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.04B | $622.7M | +43.83% |
| 2024 | 2024-12-31 | $1.42B | $7.6M | +0.54% |
| 2023 | 2023-12-31 | $1.41B | $106.4M | +8.14% |
| 2022 | 2022-12-31 | $1.31B | $545.9M | +71.76% |
| 2021 | 2021-12-31 | $760.8M | $506.4M | +199.06% |
| 2020 | 2020-12-31 | $254.4M | −$34.5M | −11.94% |
| 2019 | 2019-12-31 | $288.9M | $220.4M | +322.06% |
| 2018 | 2018-12-31 | $68.4M | $34.8M | +103.64% |
| 2017 | 2017-12-31 | $33.6M | −$116.2M | −77.57% |
| 2016 | 2016-12-31 | $149.9M | $143.3M | +2191.04% |
| 2015 | 2015-12-31 | $6.5M | $18.1M | — |
| 2014 | 2014-12-31 | −$11.5M | −$33.9M | — |
| 2013 | 2013-12-31 | $22.4M | $90.8M | — |
| 2012 | 2012-12-31 | −$68.4M | −$16.0M | — |
| 2011 | 2011-12-31 | −$52.4M | — | — |
Halozyme Therapeutics quarterly net debt
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.02B | $539.2M | +36.53% |
| Q1 2026 | 2026-03-31 | $1.87B | $506.8M | +37.25% |
| Q4 2025 | 2025-12-31 | $2.04B | $622.7M | +43.83% |
| Q3 2025 | 2025-09-30 | $1.12B | −$261.4M | −18.93% |
| Q2 2025 | 2025-06-30 | $1.48B | $130.9M | +9.73% |
| Q1 2025 | 2025-03-31 | $1.36B | −$7.5M | −0.55% |
| Q4 2024 | 2024-12-31 | $1.42B | $7.6M | +0.54% |
| Q3 2024 | 2024-09-30 | $1.38B | $124.8M | +9.94% |
| Q2 2024 | 2024-06-30 | $1.35B | $36.9M | +2.82% |
| Q1 2024 | 2024-03-31 | $1.37B | −$64.0M | −4.47% |
| Q4 2023 | 2023-12-31 | $1.41B | $106.4M | +8.14% |
| Q3 2023 | 2023-09-30 | $1.26B | −$109.0M | −7.98% |
| Q2 2023 | 2023-06-30 | $1.31B | $244.4M | +22.97% |
| Q1 2023 | 2023-03-31 | $1.43B | $759.6M | +112.96% |
| Q4 2022 | 2022-12-31 | $1.31B | $545.9M | +71.76% |
| Q3 2022 | 2022-09-30 | $1.36B | $1.07B | +357.66% |
| Q2 2022 | 2022-06-30 | $1.06B | $721.4M | +210.54% |
| Q1 2022 | 2022-03-31 | $672.5M | $382.7M | +132.09% |
| Q4 2021 | 2021-12-31 | $760.8M | $506.4M | +199.06% |
| Q3 2021 | 2021-09-30 | $298.2M | −$35.2M | −10.56% |
| Q2 2021 | 2021-06-30 | $342.6M | $79.5M | +30.20% |
| Q1 2021 | 2021-03-31 | $289.7M | $621,000 | +0.21% |
| Q4 2020 | 2020-12-31 | $254.4M | −$34.5M | −11.94% |
| Q3 2020 | 2020-09-30 | $333.4M | $374.9M | — |
| Q2 2020 | 2020-06-30 | $263.2M | $307.9M | — |
| Q1 2020 | 2020-03-31 | $289.1M | $322.2M | — |
| Q4 2019 | 2019-12-31 | $288.9M | $220.4M | +322.06% |
| Q3 2019 | 2019-09-30 | −$41.5M | −$44.4M | — |
| Q2 2019 | 2019-06-30 | −$44.7M | −$68.6M | — |
| Q1 2019 | 2019-03-31 | −$33.1M | −$37.7M | — |
| Q4 2018 | 2018-12-31 | $68.4M | $34.8M | +103.64% |
| Q3 2018 | 2018-09-30 | $2.9M | $21.9M | — |
| Q2 2018 | 2018-06-30 | $23.9M | −$26.9M | −52.91% |
| Q1 2018 | 2018-03-31 | $4.7M | −$134.6M | −96.64% |
| Q4 2017 | 2017-12-31 | $33.6M | −$116.2M | −77.57% |
| Q3 2017 | 2017-09-30 | −$19.0M | −$157.6M | — |
| Q2 2017 | 2017-06-30 | $50.8M | −$92.8M | −64.65% |
| Q1 2017 | 2017-03-31 | $139.2M | $39.7M | +39.93% |
| Q4 2016 | 2016-12-31 | $149.9M | $143.3M | +2191.04% |
| Q3 2016 | 2016-09-30 | $138.6M | $176.0M | — |
| Q2 2016 | 2016-06-30 | $143.6M | $171.3M | — |
| Q1 2016 | 2016-03-31 | $99.5M | $97.8M | +5760.25% |
| Q4 2015 | 2015-12-31 | $6.5M | $18.1M | — |
| Q3 2015 | 2015-09-30 | −$37.4M | −$30.8M | — |
| Q2 2015 | 2015-06-30 | −$27.7M | −$15.1M | — |
| Q1 2015 | 2015-03-31 | $1.7M | $30.9M | — |
| Q4 2014 | 2014-12-31 | −$11.5M | −$33.9M | — |
| Q3 2014 | 2014-09-30 | −$6.6M | −$15.5M | — |
| Q2 2014 | 2014-06-30 | −$12.5M | −$12.8M | — |
| Q1 2014 | 2014-03-31 | −$29.2M | −$19.9M | — |
| Q4 2013 | 2013-12-31 | $22.4M | $90.8M | — |
| Q3 2013 | 2013-09-30 | $8.8M | $96.5M | — |
| Q2 2013 | 2013-06-30 | $247,507 | $102.3M | — |
| Q1 2013 | 2013-03-31 | −$9.2M | $107.4M | — |
| Q4 2012 | 2012-12-31 | −$68.4M | −$16.0M | — |
| Q3 2012 | 2012-09-30 | −$87.6M | — | — |
| Q2 2012 | 2012-06-30 | −$102.0M | — | — |
| Q1 2012 | 2012-03-31 | −$116.6M | — | — |
| Q4 2011 | 2011-12-31 | −$52.4M | — | — |
Halozyme Therapeutics net debt trends
Over the last five fiscal years, Halozyme Therapeutics's net debt increased from $254.4M to $2.04B, a change of $1.79B. The latest reported quarter, Q2 2026, shows $2.02B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Halozyme Therapeutics source filings ↗